BDKRB1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL571391	1.00	20/20
SCHEMBL1179975	0.67	20/20
SCHEMBL701969	0.65	20/20
SCHEMBL1180207	0.64	20/20
SCHEMBL571420	0.64	20/20
SCHEMBL699680	0.63	20/20
SCHEMBL700853	0.62	20/20
SCHEMBL1181196	0.62	20/20
SCHEMBL700976	0.62	20/20
SCHEMBL699766	0.61	20/20
SCHEMBL1179910	0.61	20/20
SCHEMBL701000	0.60	20/20
Trifluoroacetamide (SCHEMBL304125)	0.56	20/20
SCHEMBL493067	0.54	20/20
SCHEMBL701180	0.54	20/20
SCHEMBL493313	0.53	20/20
SCHEMBL492599	0.52	20/20
SCHEMBL493158	0.52	20/20
SCHEMBL493353	0.52	20/20
SCHEMBL493459	0.51	20/20

Clinical trials — most relevant to BDKRB1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Kallikrein-kinin (KKS) and Renin-angiotensin-aldosterone System (RAAS) in Primary Aldosteronism	PHASE4	COMPLETED
Clonidine vs. Dexmedetomidine in Agitated Delirium in Intensive Care Patients	PHASE4	UNKNOWN
Bradykinin Receptor Antagonism During Cardiopulmonary Bypass	PHASE2/PHASE3	COMPLETED
Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II	PHASE3	COMPLETED
Efficacy and Safety Study of Azilsartan Medoxomil Compared to Ramipril for Treating Essential Hypertension	PHASE3	COMPLETED
The Role of Angiotensin Type I Receptor in the Regulation of Human Coronary Vascular Function	PHASE3	COMPLETED
The Role of Angiotensin Type I Receptor in the Regulation of Human Peripheral Vascular Function	PHASE3	COMPLETED
Bradykinin Receptors and Pain	PHASE2	COMPLETED
Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients	PHASE1/PHASE2	RECRUITING
Examination of the Bronchoprotective Effect of Endothelin Receptor Blockade in Asthma	PHASE2	UNKNOWN
Impact of Exercise Training on Endothelial Function in CAD	PHASE2	UNKNOWN
Vasoreactivity in Carriers of Genetic Polymorphisms	PHASE1	UNKNOWN
Effects of Miconazole on Blood Flow	PHASE1	COMPLETED
Propranolol for the Treatment of Traumatic Brain Injury	EARLY_PHASE1	UNKNOWN
Study of the Interaction Between the Cells Lining Blood Vessels and Angiotensin-Converting Enzyme	nan	COMPLETED
Involvement of Monocytic B1 and B2 Receptors in Inflammation and Chronic Vascular Disease in Patients With Hereditary Bradykinetic Angioedema	nan	COMPLETED
Long Term Effects of Enalapril and Losartan on Genetic Heart Disease	nan	COMPLETED
Autonomic Nervous System Profile in Hereditary Angioedema	nan	COMPLETED
Racial Variation in ACE--Genetic and Physiologic Bases	nan	COMPLETED
B2 Adrenergic Receptor Gene Polymorphism in Bronchial Asthma	nan	UNKNOWN
Forced Oscillometry in Infants With Bronchopulmonary Dysplasia	nan	RECRUITING
Selective Activation of the Adrenomedullin Receptors in Migraine	nan	NOT_YET_RECRUITING
Efficacy and Safety of Angiotensin II Use in Coronavirus Disease(COVID)-19 Patients With Acute Respiratory Distress Syndrome	nan	UNKNOWN
The Effect of Ischaemic-Reperfusion in Man - A Bradykinin Dependent Pathway	nan	COMPLETED
Validation of Laser Doppler Flowmetry to Identify Allergic Rhinitis Patients With Pharmacogenetic Alterations in Histamine Metabolism	nan	COMPLETED
Role of Endothelial Cells in the Pathogenesis of Chronic Urticaria.	nan	UNKNOWN
Searching for Novel Therapeutic Approaches in Migraine Patients Resistant to Treatments	nan	RECRUITING
Changes After Angiotensin Converting Enzyme (ACE) Inhibitor Replacement by Angiotensin II Receptor Type I (AT1) Blocker	nan	UNKNOWN
Evaluating Long Acting Beta Agonists Used to Treat Asthma Among Those With Either Arg/Arg or Gly/Gly Genotypes	nan	COMPLETED
Role of B2 Adrenergic Receptors in Labor Pain	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a BDKRB1 binder may also engage these)

Protein	Name	Similarity
Q8HZP3	—	1.000	Q8HZP3 →
Q95L01	—	1.000	Q95L01 →
Q8HZP2	—	1.000	Q8HZP2 →
Q3BCU0	—	1.000	Q3BCU0 →
Q8HZP1	—	0.992	Q8HZP1 →
Q8HZN9	—	0.989	Q8HZN9 →
P48748	—	0.988	P48748 →
Q61125	—	0.983	Q61125 →
Q9BDQ5	—	0.973	Q9BDQ5 →
P97583	—	0.971	P97583 →
Q28642	—	0.969	Q28642 →
Q9GLX8	—	0.969	Q9GLX8 →
F7EQ49	—	0.966	F7EQ49 →
O88410	—	0.964	O88410 →
A0T2N3	—	0.963	A0T2N3 →
Q9JII9	—	0.962	Q9JII9 →
Q7SZP9	—	0.961	Q7SZP9 →
GPER1	G-protein coupled estrogen receptor 1	0.960	landscape →
LTB4R	Leukotriene B4 receptor 1	0.959	landscape →
Q5KSK8	—	0.958	Q5KSK8 →
Q5MD61	—	0.957	Q5MD61 →
Q867B2	—	0.957	Q867B2 →
O08878	—	0.956	O08878 →
Q8BMP4	—	0.956	Q8BMP4 →
CXCR3	C-X-C chemokine receptor type 3	0.955	landscape →
Q3T181	—	0.955	Q3T181 →
O70526	—	0.954	O70526 →
P25023	—	0.951	P25023 →
GPR35	G-protein coupled receptor 35	0.950	landscape →
Q8VIH9	—	0.950	Q8VIH9 →